Evidence map›Paper›PMID 26703235›Full record

ArticlePhysiology & behavior2016

Interferon-alpha-induced inflammation is associated with reduced glucocorticoid negative feedback sensitivity and depression in patients with hepatitis C virus.

Jennifer C Felger, Ebrahim Haroon, Bobbi J Woolwine, Charles L Raison, Andrew H Miller

Open access · greenAbstract read
In one paragraph

Article in Physiology & behavior, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Can treatment of obesity reduce depression or vice versa?Journal of psychiatry & neuroscience : JPN · 2021
    Article
  11. Depression, dementia and immune dysregulation.Brain : a journal of neurology · 2021
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Decreased Quality of Life in Individuals with Type 2 Diabetes Mellitus Is Associated with Emotional Distress.International journal of environmental research and public health · 2019
    Article
  18. Review
  19. Review
  20. Immune and Neuroendocrine Mechanisms of Stress Vulnerability and Resilience.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jennifer C FelgerDepartment of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA 30322, United States; The Winship Cancer Institute, Emory University, Atlanta, GA 30322, United States. Electronic address: jfelger@gmail.com.
Ebrahim HaroonDepartment of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA 30322, United States; The Winship Cancer Institute, Emory University, Atlanta, GA 30322, United States.
Bobbi J WoolwineDepartment of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA 30322, United States.
Charles L RaisonSchool of Human Ecology, University of Wisconsin-Madison, Madison, WI 53706, United States; Department of Psychiatry, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53706, United States.
Andrew H MillerDepartment of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA 30322, United States; The Winship Cancer Institute, Emory University, Atlanta, GA 30322, United States.
Emory University · USUniversity of Wisconsin–Madison · US

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025008 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$29.0M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
X LINKED NYSTAGMUS SYNDROME WITH FEATURES OF ALBINISMM01RR000039 · NCRR · EMORY UNIVERSITY · PI QUYYUMI, ARSHED A · 1985 to 2007
$21.3M
Inflammation-Induced CNS Glutamate as a Function of Depression in Middle AgeR01MH107033 · NIMH · EMORY UNIVERSITY · PI HAROON, EBRAHIM · 2016 to 2021
$2.2M
Cytokine-CRH Interactions in IFN-alfa-Induced DepressionR01MH070553 · NIMH · EMORY UNIVERSITY · PI RAISON, CHARLES · 2005 to 2009
$1.6M
IFN ALPHA-INDUCED DEPRESSIONR01MH060723 · NIMH · EMORY UNIVERSITY · PI MILLER, ANDREW H · 2000 to 2003
$1.4M
HIV/AIDS CLINICAL RESEARCH TRAINING PROGRAMT32MH020018 · NIMH · EMORY UNIVERSITY · PI MILLER, ANDREW H · 1998 to 2008
$1.3M
Pathophysiology of IFN-alpha-induced Sleep DisturbancesR01HL073921 · NHLBI · EMORY UNIVERSITY · PI MILLER, ANDREW H · 2004 to 2008
$1.3M
Neuroimmune Mechanisms of Glucocorticoid ResistanceR01MH075102 · NIMH · EMORY UNIVERSITY · PI MILLER, ANDREW H · 2006 to 2010
$1.0M
MR SPECTROSCOPY TO REVEAL CNS MECHANISMS OF CYTOKINE-INDUCED BEHAVIORAL CHANGEK23MH091254 · NIMH · EMORY UNIVERSITY · PI HAROON, EBRAHIM · 2010 to 2014
$883k
NCATS NIH HHS UL1 TR000454NCI NIH HHS P30 CA138292NCRR NIH HHS M01 RR000039NCRR NIH HHS UL1 RR025008NHLBI NIH HHS R01 HL073921NIAID NIH HHS P30 AI050409NIMH NIH HHS K05 MH069124NIMH NIH HHS K23 MH064619NIMH NIH HHS K23 MH091254NIMH NIH HHS R01 MH060723NIMH NIH HHS R01 MH070553NIMH NIH HHS R01 MH075102NIMH NIH HHS R01 MH107033NIMH NIH HHS T32 MH020018
6 · The paper itself

Abstract

Major medical illnesses are associated with increased risk for depression and alterations in hypothalamic-pituitary-adrenal (HPA) axis function. Pathophysiological processes such as inflammation that occur as a part of medical illnesses and their treatments have been shown to cause depressive symptoms, and may also affect the HPA axis. We previously reported that patients with hepatitis C virus chronically administered interferon (IFN)-alpha develop increased evening plasma cortisol concentrations and a flattened diurnal cortisol slope, which correlated with increased tumor necrosis factor (TNF) and its soluble receptor 2 (sTNFR2). Increased TNF and sTNFR2 were further correlated with depression and fatigue scores. The current study examined whether flattened cortisol slope might be secondary to reduced glucocorticoid receptor (GR) sensitivity, by measuring glucocorticoid negative feedback to dexamethasone (DEX) administration followed by corticotropin releasing hormone (CRH) challenge. In an exploratory analysis, 28 male and female patients with hepatitis C virus were studied at baseline (Visit 1) and after 12weeks (Visit 2) of either IFN-alpha plus ribavirin (n=17) or no treatment (n=11). Patients underwent dexamethasone DEX-CRH challenge, neuropsychiatric assessments, and measurement of plasma TNF and sTNFR2 during each visit. IFN-alpha did not affect neuroendocrine responses following CRH but did increase post-DEX cortisol, which was correlated with flattening of the diurnal cortisol slope (r=0.57, p=0.002) and with increased depression scores (r=0.38, p=0.047). Furthermore, the change in post-DEX cortisol was associated with IFN-alpha-induced increase in sTNFR2 (r=0.51, p=006), which was in turn correlated with depression (r=0.63, p<0.001) and fatigue (r=0.51, p=0.005) scores. Whereas the relationship between sTNFR2 and depression scores were independent of the change in post-DEX cortisol, the correlation between post-DEX cortisol and depression scores was not significant when controlling for sTNFR2. These findings suggest that inflammation induced in patients with hepatitis C virus during IFN-alpha therapy precipitates decreased GR sensitivity to lead to a flattened diurnal cortisol slope. Decreased GR sensitivity may in turn further increase inflammation and its ultimate effects on behavior. Treatments that target inflammation and/or GR sensitivity may reduce depressive symptoms associated with medical illnesses.

Indexed as

Adrenocorticotropic HormoneAdultAntiviral AgentsArea Under CurveCorticotropin-Releasing HormoneDepressionDexamethasoneFatigueFemaleGlucocorticoidsHepatitis CHumansHydrocortisoneInflammationInterferon-alphaLongitudinal StudiesAdrenocorticotropic HormoneAntiviral AgentsCorticotropin-Releasing HormoneDexamethasoneGlucocorticoidsHydrocortisoneInterferon-alphaReceptors, Tumor Necrosis Factor, Type IIRibavirinTumor Necrosis Factor-alphaDepressionDexamethasoneFatigueHepatitis C virusHPA-axisInflammation

Identifiers

PMID26703235
PMCPMC4912474
OpenAlexW2209156328

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.